causes a serious disease for which an effective vaccine has not been developed. A recombinant glycoprotein D (gD) vaccine (HerpeVac) recently failed to show efficacy in a phase III trial ... level of protection with a…
important goal in a successful vaccine formulation is to identify adjuvants that promote the appropriate immune responses and are safe for use in humans. The majority of adjuvants elicit humoral ... desired strong…
prescribe these antibiotics. The objective of this study is to develop a molecular kit (primers) to early detection of the efficacy of these antibiotics (ciprofloxacin and amoxiclave) with the clinic ... susceptibility…
case and subsequent success of the polio eradication efforts worldwide. Efforts to develop a valley fever vaccine have continued for 60 years. A killed spherule vaccine protected mice and underwent ... experimental…
disease. In collaboration with Chris Broder of USUHS and Tom Geisbert, UTMB, we are developing HeV-sG, the ectodomain of HeV attachment glycoprotein, as a human vaccine and m102.4 ... over 75% protection against HeV…
against HIV has been a public health priority for over 30 years. We have developed the Full-length Single Chain (FLSC) in order to induce broader immunity, including against ... predominately monomeric and expressed the…
small percentage are progressive and even life-threatening. Infection, even in those who develop complications, induces protective cellular immunity and suggests that a preventative vaccine strategy is biologically…
novel particle platform technology designed to incorporate quality early in the development process. The PRINT technology enables unique formulation advantages that have broad implications to vaccines development and…
novel particle platform technology designed to incorporate quality early in the development process. The PRINT technology enables unique formulation advantages that have broad implications to vaccines development and…
also against different subtypes. One of the most important considerations in vaccine development is adjuvant formulation. We have designed and implemented a new technology that incorporates the TLR5 agonist flagellin…
immunity and ease of administration. VitamFero Deploys a Novel Parasite-based Vaccine Platform: VitamFero develops proprietary and unique eukaryote (apicomplexan parasites: Toxoplasma gondii or Neospora caninum)-based…
cells and induce robust immunity in the absence of exogenous adjuvant formulation. Based on this technology, we developed recombinant lipidated dengue envelope protein domain IIIs as vaccine candidates against dengue…
research group is tasked with integrating immunology and bioengineering to facilitate the development of vaccine formulation and delivery for the induction of broadened and appropriate immune responses. During the past
Plasmodium falciparum, but Plasmodium vivax have been ignored. However, P. vivax is able to develop hypnozoites, which increases the morbidity caused by a single infection and sever malaria. Additionally ... from both…
focused towards the development of novel DCs based assays that can be used to identify and to improve adjuvant and immuno- modulator formulations. Using a functional genomics approach we have
only. T-cell proliferation and cytokine secretion was studied in mice immunized with different formulation in microsphere delivery. F1-MAP with CpG-ODN showed enhanced T-cell proliferation ... multiple antigen peptide…
innate, adaptive, and regulatory. In this context, the efficacy of subunit vaccines may require formulations that include adjuvants having pleiotropic effects on various cells of the immune system. We have ... cancer…
Mercer University, Atlanta, have developed a platform technology using nanoparticles and microparticles to deliver vaccines by the oral route of administration. This formulation technology enables us to prepare the…
then, the initiation of the proliferation mechanisms derived from this binding. This product development began in 1992, with all the preclinical testing including toxicology. The clinical experience with ... effect in…
Middle East and South America. The major challenge in scrub typhus vaccine development is how to formulate a vaccine which can provide a prolonged broad protection. Previously we have shown
moderate to heavy hookworm infection. Currently two vaccine candidate antigens are in clinical development: the Necator americanus glutathione S-transferase (Na-GST-1) and Necator americanus aspartic protease…
process development that led to the GMP manufacturing of one of the lead candidate antigens Sm- TSP-2 at a 20L scale fermentation, and its formulation for phase I clinical
neutrophils, yet, likely prevents engagement of eosinophils and basophils in the hunt for developing larvae in blood capillaries. We reasoned that polarizing ESP-induced immune responses towards a Th2 phenotype…
methods are too costly, labor-intensive, or sample-demanding for large-scale screening. We developed �immunosignaturing� which displays host antibody responses using tens of thousands of random sequence peptides…
methods are too costly, labor-intensive, or sample-demanding for large-scale screening. We developed �immunosignaturing� which displays host antibody responses using tens of thousands of random sequence peptides…
For authors and organisers
Publish, present and keep up with your field
Find the right journal for your paper and submit your manuscript.